Kyle R Noll1, Mariana E Bradshaw1, Jeffrey S Weinberg2, Jeffrey S Wefel1. 1. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 2. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
OBJECTIVE: While neurocognitive functioning (NCF) and mood disturbance share a relationship with health-related quality of life (HRQOL), few studies have examined relationships between these constructs in glioma patients prior to treatment. METHODS: Newly diagnosed patients with glioma in the left (N = 73; 49% glioblastoma) or right (N = 30; 57% glioblastoma) temporal lobe completed neuropsychological testing and self-report measures of HRQOL (Functional Assessment of Cancer Therapy (FACT)-General and Brain module) and mood (Beck Depression Inventory-Second Edition and State-Trait Anxiety Inventory). RESULTS: Verbal learning and memory, executive function, and language abilities were associated with various HRQOL scales. Stepwise linear regression showed that verbal learning predicted scores on the general well-being scale and brain module, processing speed predicted social well-being scores, and executive functioning predicted functional well-being scores on the FACT. Upper extremity strength also predicted scores on the functional well-being subscale and brain module. Mood was more strongly associated with HRQOL domains than NCF, with depressive symptoms accounting for a large proportion of variance across most subscales. CONCLUSIONS: In patients with temporal lobe glioma, depressive symptoms are strongly related to most aspects of HRQOL but not with NCF. NCF, specifically verbal learning and memory, executive functioning, and processing speed, also show direct relationships with numerous aspects of HRQOL. These findings underscore the importance of multimodal assessment of NCF and mood in this population.
OBJECTIVE: While neurocognitive functioning (NCF) and mood disturbance share a relationship with health-related quality of life (HRQOL), few studies have examined relationships between these constructs in gliomapatients prior to treatment. METHODS: Newly diagnosed patients with glioma in the left (N = 73; 49% glioblastoma) or right (N = 30; 57% glioblastoma) temporal lobe completed neuropsychological testing and self-report measures of HRQOL (Functional Assessment of Cancer Therapy (FACT)-General and Brain module) and mood (Beck Depression Inventory-Second Edition and State-Trait Anxiety Inventory). RESULTS:Verbal learning and memory, executive function, and language abilities were associated with various HRQOL scales. Stepwise linear regression showed that verbal learning predicted scores on the general well-being scale and brain module, processing speed predicted social well-being scores, and executive functioning predicted functional well-being scores on the FACT. Upper extremity strength also predicted scores on the functional well-being subscale and brain module. Mood was more strongly associated with HRQOL domains than NCF, with depressive symptoms accounting for a large proportion of variance across most subscales. CONCLUSIONS: In patients with temporal lobe glioma, depressive symptoms are strongly related to most aspects of HRQOL but not with NCF. NCF, specifically verbal learning and memory, executive functioning, and processing speed, also show direct relationships with numerous aspects of HRQOL. These findings underscore the importance of multimodal assessment of NCF and mood in this population.
Authors: Robert Perneczky; Corina Pohl; Christian Sorg; Julia Hartmann; Natasa Tosic; Timo Grimmer; Sandra Heitele; Alexander Kurz Journal: Int J Geriatr Psychiatry Date: 2006-02 Impact factor: 3.485
Authors: Elena Lamperti; Giuseppe Pantaleo; Claudia Yvonne Finocchiaro; Antonio Silvani; Andrea Botturi; Paola Gaviani; Lucio Sarno; Andrea Salmaggi Journal: Support Care Cancer Date: 2011-07-03 Impact factor: 3.603
Authors: Lin Lin; Hui-Hsun Chiang; Alvina A Acquaye; Elizabeth Vera-Bolanos; Mark R Gilbert; Terri S Armstrong Journal: Cancer Date: 2013-05-09 Impact factor: 6.860
Authors: Julia Day; David C Gillespie; Alasdair G Rooney; Helen J Bulbeck; Karolis Zienius; Florien Boele; Robin Grant Journal: Curr Treat Options Neurol Date: 2016-05 Impact factor: 3.598
Authors: Christina Weyer-Jamora; Melissa S Brie; Tracy L Luks; Ellen M Smith; Steve E Braunstein; Javier E Villanueva-Meyer; Paige M Bracci; Susan Chang; Shawn L Hervey-Jumper; Jennie W Taylor Journal: Neurooncol Pract Date: 2020-11-04
Authors: Christina Weyer-Jamora; Melissa S Brie; Tracy L Luks; Ellen M Smith; Shawn L Hervey-Jumper; Jennie W Taylor Journal: Neurosurgery Date: 2021-11-18 Impact factor: 5.315
Authors: Emma van Kessel; Anniek E Baumfalk; Martine J E van Zandvoort; Pierre A Robe; Tom J Snijders Journal: J Neurooncol Date: 2017-05-31 Impact factor: 4.130
Authors: Mia Salans; Michelle D Tibbs; Minh-Phuong Huynh-Le; Anthony Yip; Kathryn Tringale; Roshan Karunamuni; Ronghui Xu; Anny Reyes; Anna Christina Macari; Tonya Pan-Weisz; Carrie R McDonald; Jona A Hattangadi-Gluth Journal: Int J Radiat Oncol Biol Phys Date: 2021-06-06 Impact factor: 7.038